A method for purifying foot-and-mouth disease inactivated antigen protein

By using PEI for initial impurity removal and the synergistic effect of low-concentration PEG and chloroform, the problem of poor purification effect and poor applicability of foot-and-mouth disease inactivated antigen protein in existing technologies has been solved, achieving a highly efficient and environmentally friendly purification effect that is suitable for industrial production.

CN116751265BActive Publication Date: 2026-11-17SHANGHAI SHEN LIAN BIOMEDICAL CORP
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310686711.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-09
Publication Date
2026-11-17
Estimated Expiration
2043-06-09

AI Technical Summary

Technical Problem

Existing methods for purifying foot-and-mouth disease inactivated antigen proteins have limited effectiveness in removing impurities and poor applicability to different upstream processes, posing risks of chloroform residue and hollow fiber column contamination.

Method used

PEI was used for initial impurity removal, followed by ultrafiltration concentration using a hollow fiber column. Then, low concentrations of PEG and chloroform were added for synergistic effect. By adjusting the salt concentration, efficient removal of impurity proteins was achieved while maintaining the stability and homogeneity of the antigen proteins.

Benefits of technology

It improves the purity of antigen proteins, reduces the amount of chloroform used, reduces environmental pollution, enhances the universality and purification effect of the method, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116751265B_ABST
    Figure CN116751265B_ABST
Patent Text Reader

Abstract

This invention relates to a method for purifying foot-and-mouth disease (FMD) inactivated antigen protein. The purification method includes: A1, adding PEI; A2, ultrafiltration concentration using a hollow fiber column; A3, stepwise addition of PEG and chloroform; A4, adding an appropriate amount of salt; A5, dissolving the precipitate using a reconstituted solution after adding PEG. This invention, by retaining the initial impurity removal using PEI, allows the antigen solution to reach a relatively pure state before concentration, resulting in better purification and facilitating subsequent concentration. After concentration using a hollow fiber column, a low concentration of PEG and chloroform is used in combination, utilizing their synergistic effect to efficiently remove impurities from the FMD antigen solution. These operations, while achieving the initial purification objective, combined with salt concentration adjustment, ensure a relatively homogeneous state even for antigen solutions with differences, making the subsequent PEG precipitation purification process parameters universally applicable and achieving a stable yield.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention pertains to vaccine preparation in the field of biomedicine, specifically relating to a method for purifying foot-and-mouth disease inactivated antigen protein. Background Technology

[0002] Foot-and-mouth disease (FMD) is an acute, febrile, and highly contagious animal disease caused by the foot-and-mouth disease virus. It primarily affects cloven-hoofed animals, and its clinical diagnostic features include vesicles on the oral mucosa, hooves, and mammary gland skin. While the mortality rate in adult animals infected with FMD is generally low, the morbidity rate can reach 100%. Affected animals develop numerous vesicles on their mouth and hooves, exhibit lethargy, and consequently experience a sharp decline in livestock production. Young animals infected with FMD often die suddenly without showing symptoms, with a mortality rate reaching 100% in severe cases. Due to the rapid spread, difficulty in prevention and control, and limited remedial measures, each outbreak necessitates the slaughter and mass incineration of infected livestock to prevent future outbreaks, resulting in significant economic losses to the livestock industry.

[0003] Currently, purification methods for inactivated foot-and-mouth disease (FMD) antigen proteins have limited effectiveness in removing impurities and poor applicability to antigens from different upstream processes. Chinese patent application number 200910092433.3 discloses a process for purifying FMD vaccine antigens, which uses only 0.5%–2% chloroform and employs precipitation to remove impurities from the FMD antigen solution. This method has limited effectiveness in removing impurities. Furthermore, chloroform has a certain solubility in water; after adding chloroform to precipitate impurities, chloroform residue remains in the supernatant. Using this solution directly to prepare vaccines without subsequent processes to remove residual chloroform poses a risk. Chinese patent application number 201210112283.X discloses a method for concentrating and purifying FMD vaccines, which includes: 1) removing large particles from the antigen using a continuous flow centrifuge; 2) treating the antigen solution after step 1) using a hollow fiber ultrafiltration system; and 3) treating the circulating liquid after step 2) with PEG6000. This purification method has significant shortcomings: First, relying solely on centrifugation to remove large particles from the antigen leaves a large amount of contaminating proteins in the antigen solution, putting pressure on subsequent concentration steps. This includes: excessive protein retention in the hollow fiber column, filter cake accumulation, increased system pressure, prolonged concentration time, and even the risk of contamination of the hollow fiber column membrane pores by contaminating proteins. Second, the precipitation effect of PEG on foot-and-mouth disease antigen proteins depends on the state of the antigen buffer solution; different protein and salt concentrations require different optimal PEG dosages. Optimization or changes to the upstream culture process can render the previously established PEG precipitation protocol inapplicable, necessitating re-experimentation and adjustment of downstream purification parameters (PEG dosage). This purification method has poor universal applicability to antigens from different upstream processes. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings and deficiencies of existing technologies and provide a method for purifying foot-and-mouth disease (FMD) inactivated antigen proteins. By using PEI (polyethylene glycol) for preliminary impurity removal, the antigen solution reaches a relatively pure state before concentration, resulting in better purification and facilitating subsequent concentration. After concentration using a hollow fiber column, a low concentration of PEG and chloroform is used in combination. The synergistic effect of their simultaneous presence efficiently removes impurities from the FMD antigen solution. These operations, while achieving the initial purification objective, combined with salt concentration adjustment, ensure that even antigen solutions with differences can reach a relatively homogeneous state, making the subsequent PEG precipitation purification process parameters universally applicable and achieving stable yields.

[0005] The objective of this invention can be achieved through the following methods:

[0006] This invention provides a method for purifying foot-and-mouth disease inactivated antigen protein, the method comprising the following steps:

[0007] A1. Add PEI to the antigen solution, centrifuge to remove the precipitate, and retain the supernatant;

[0008] A2. The supernatant (foot-and-mouth disease inactivated virus antigen solution) obtained in step A1 was concentrated by ultrafiltration using a hollow fiber column;

[0009] A3. Add PEG to the concentrated antigen solution from step A2, stir and mix well, then add chloroform, stir and mix again, centrifuge to remove the precipitate, and retain the supernatant.

[0010] A4. Add an appropriate amount of salt to the supernatant obtained in step A3 (to adjust the state of the antigen solution);

[0011] A5. Add PEG to the supernatant obtained in step A4, centrifuge to collect the precipitate (foot-and-mouth disease antigen protein), dissolve the precipitate with a reconstitution solution, and filter to remove bacteria.

[0012] In one embodiment of the present invention, in step A1, the antigen solution is obtained by culturing foot-and-mouth disease virus in BHK-21 cells and then inactivating it.

[0013] As one embodiment of the present invention, in step A1, the molecular weight of PEI (polyethyleneimine) is 1800-130000, and the concentration of PEI in the antigen solution is 0.002-0.01%m / V.

[0014] As one embodiment of the present invention, in step A2, the pore size of the hollow fiber is 300-500KD, and it is concentrated to 1 / 10-1 / 20 of the original volume.

[0015] In one embodiment of the present invention, in step A3, the molecular weight of PEG (polyethylene glycol) is 4000-8000, the concentration of PEG in the antigen solution is 0.2-1.0% m / V, and the concentration of chloroform in the antigen solution is 2-5% V / V.

[0016] In one embodiment of the present invention, in step A3, the molecular weight of the PEG is 6000.

[0017] As one embodiment of the present invention, in step A1 or step A3, the method for centrifuging to remove precipitates is: using a disc centrifuge with a rotation speed of 5000-7000 rpm.

[0018] As one embodiment of the present invention, in step A4, the salt includes at least one of 100-200mM magnesium chloride or sodium sulfate and 500-1000mM sodium chloride.

[0019] In one embodiment of the present invention, in step A4, the salt is 100-200mM magnesium chloride.

[0020] In one embodiment of the present invention, in step A5, the molecular weight of the PEG is 4000-8000, and the concentration of PEG in the supernatant is 5-7% m / V.

[0021] In one embodiment of the present invention, in step A5, the molecular weight of the PEG is 6000.

[0022] As one embodiment of the present invention, in step A5, the method for centrifuging to remove precipitate is: using a disc centrifuge with a rotation speed of 6000-8000 rpm.

[0023] In one embodiment of the present invention, in step A5, the reconstitution solution is 5-20 mM Hepes, wherein the Hepes includes 400-600 mM sodium chloride, 1-5 mM magnesium chloride, and has a pH of 7.6-8.0.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] (1) By adding PEI during the centrifugation process to remove cell debris, the present invention removes acidic proteins and nucleic acids from the foot-and-mouth disease antigen solution, thereby improving the purity of the foot-and-mouth disease antigen and facilitating subsequent operations. In particular, it can effectively avoid the risk of contamination of the hollow fiber column membrane pores by impurities in the foot-and-mouth disease antigen solution during the subsequent concentration process.

[0026] (2) Unlike existing purification methods that use high-concentration PEG precipitation and chloroform extraction, this invention adds a lower concentration of PEG and chloroform to the concentrated foot-and-mouth disease antigen solution. The low concentration of PEG can compete with the hydration membrane on the surface of impurity proteins, causing the impurity proteins to directly contact the buffer solution. This allows the subsequently added chloroform to fully interact with the impurity proteins, causing them to denature rapidly and achieving a synergistic precipitation effect. By utilizing the synergistic effect of the two reagents in protein precipitation and retaining most of the foot-and-mouth disease antigen proteins in the supernatant, a large amount of impurity proteins in the antigen concentrate are removed. At the same time, the amount of toxic and harmful chloroform used in the purification process is greatly reduced, avoiding environmental pollution.

[0027] (3) This invention removes impurities from the antigen solution in two steps through the synergistic effect of PEI and PEG-chloroform. By adjusting the salt concentration in the antigen solution, the antigen solution with different upstream culture process parameters can reach a uniform state with low impurity protein content and high salt content, which improves the universal applicability of this method to samples with different upstream processes.

[0028] (4) The purification method of the present invention has the characteristics of simple operation, low equipment requirements, low purification cost, high throughput and high total yield, and is environmentally friendly and suitable for industrial production. Attached Figure Description

[0029] Other features, objects, and advantages of the present invention will become more apparent from the following detailed description of non-limiting embodiments with reference to the accompanying drawings:

[0030] Figure 1 HPLC chromatogram for antigen purification. Detailed Implementation

[0031] The present invention will now be described in detail with reference to the accompanying drawings and specific embodiments. The following examples are implemented under the premise of the technical solution of the present invention, providing detailed implementation methods and specific operating procedures, which will help those skilled in the art to further understand the present invention. It should be noted that the scope of protection of the present invention is not limited to the following embodiments; any adjustments and improvements made under the concept of the present invention are all within the scope of protection of the present invention.

[0032] It should be noted that the final concentration in this article refers to the concentration in the solution system at the current step.

[0033] Example 1: PEI Impurity Removal

[0034] Reagent: PEI (Aladdin), diluted with purified water to a concentration of 10% (m / V) for PEI with molecular weights of 1800, 10000, 70000 and 130000, adjusted to pH 7.8-8.0 with sulfuric acid, and sterilized at 121℃ for 20 minutes before use.

[0035] Antigen solution: Foot-and-mouth disease virus was cultured in suspension in BHK-21 cells and then inactivated.

[0036] PEI treatment: Take four groups of antigen solutions and add pre-diluted PEI with a concentration of 10% (m / V) and molecular weights of 1800, 10000, 70000, and 130000, respectively, to make their final concentrations (m / V) 0.01%, 0.01%, 0.005%, and 0.002%. For the control group, add 0.01% of the total antigen volume of water for injection instead of PEI.

[0037] Total protein assay: 1 ml of sample was taken from each group, appropriately diluted, and detected using the modified Lowry method. Pierce TM The modified Lowry protein assay kit was purchased from Thermo Fisher Scientific. To avoid the added PEI affecting the test results, all samples were ultrafiltered and the medium was replaced using a 5KD ultrafiltration tube before testing.

[0038] Total 146S antigen content determination: 20ml of sample was taken from each sample and the sucrose density gradient method was used for detection, in accordance with the testing procedures for foot-and-mouth disease vaccine semi-finished products as per the Ministry of Agriculture Announcement No. 2617.

[0039] Table 1

[0040]

[0041] The precipitation effect of PEI on proteins is based on its own positive charge, which attracts negatively charged nucleic acids and acidic proteins in the antigen solution, thus forming a precipitate. In other words, the precipitation effect of PEI is a charge neutralization reaction. As shown in Table 1, PEI concentrations of 0.002–0.01% can effectively remove impurities without causing significant loss of 146S antigen protein.

[0042] Example 2 Ultrafiltration Concentration

[0043] Reagent: PEI70000 (Aladdin), diluted with purified water to a concentration of 10% (m / V), pH adjusted to 7.8-8.0 with sulfuric acid, sterilized at 121℃ for 20 minutes before use.

[0044] Antigen solution: Foot-and-mouth disease virus was cultured in suspension in BHK-21 cells and then inactivated.

[0045] PEI treatment: Add PEI with a molecular weight of 70,000 to the antigen solution, with a final concentration of 0.005% (m / V). After stirring and mixing, centrifuge at 5000 rpm using a disc centrifuge, discard the lower precipitate, and retain the supernatant. For the control group, add 0.005% of the total antigen volume of water for injection instead of PEI.

[0046] Ultrafiltration concentration: The supernatant antigen solution obtained in the previous step is concentrated to 1 / 20 of its original volume using a 300KD hollow fiber column.

[0047] Turbidity determination: Take 8 ml of sample for each group and measure the turbidity directly using a turbidimeter.

[0048] Table 2

[0049]

[0050] From the comparison of the PEI-treated group and the control group in Table 2, the turbidity of the antigen solution decreased by 39.5% after PEI treatment. The concentration process can be completed without adding higher pressure, and the concentration time is shorter.

[0051] Example 3: Synergistic Impurity Removal with PEG and Chloroform

[0052] Reagents: PEG6000 (Merck), prepared as a 42% (m / V) PEG solution with water for injection, sterilized at 121°C for 20 minutes. Chloroform (Sinopharm Group).

[0053] Antigen solution: Foot-and-mouth disease virus was cultured in suspension in BHK-21 cells and then inactivated.

[0054] PEI treatment: Add PEI with a molecular weight of 70,000 and a final concentration of 0.005% (m / V) to the antigen solution, stir and mix well, then centrifuge at 6000 rpm using a disc centrifuge, discard the lower precipitate and retain the supernatant.

[0055] Ultrafiltration concentration: 500KD hollow fiber column, concentrated to 1 / 20 of the original volume.

[0056] PEG and chloroform were used to synergistically treat contaminating proteins: For treatment groups 1-3 and control groups 1-3, PEG was added first according to the amounts listed in Table 3. After mixing, chloroform was added, and the mixture was mixed again. The mixture was centrifuged at 60,000 rpm, the lower precipitate was discarded, and the supernatant was retained. For control group 4, PEG was added to the antigen solution at a final concentration of 4% (m / V), mixed, and allowed to stand for 3.5 hours. The mixture was then centrifuged at 6,000 rpm for 10 minutes. The precipitate was reconstituted with an equal volume of 20 mM Hepes buffer (containing 500 mM sodium chloride, 2 mM magnesium chloride, and adjusted to pH 7.83 with sodium hydroxide). An equal volume of chloroform (final concentration 50% V / V) was added to the reconstituted antigen solution, and the mixture was shaken for 2 minutes. The mixture was then centrifuged at 8,000 rpm for 10 minutes, the precipitate was discarded, and the supernatant was retained.

[0057] Total protein assay: Take 1 ml of sample from each sample, dilute appropriately, and analyze using the modified Lowry method. Pierce TMThe modified Lowry protein assay kit was purchased from Thermo Fisher Scientific. To avoid the influence of added PEI and chloroform on the test results, all samples were ultrafiltered and the medium was replaced using a 5KD ultrafiltration tube before testing.

[0058] Total 146S antigen content determination: 20ml of sample was taken from each sample and the sucrose density gradient method was used for detection, in accordance with the testing procedures for foot-and-mouth disease vaccine semi-finished products as per the Ministry of Agriculture Announcement No. 2617.

[0059] Table 3

[0060]

[0061]

[0062] Using low concentrations of PEG alone has limited effectiveness in removing impurities from the antigen solution. However, when PEG and chloroform are used together, the protein removal effect is higher than when PEG and chloroform are used alone. PEG can compete for the hydration membrane on the protein surface, causing the protein to come into direct contact with the buffer solution. Adding chloroform at this time allows the chloroform to fully react with the protein, causing rapid protein denaturation and achieving a synergistic effect of protein precipitation. Simultaneously, the antigen recovery rate shows that foot-and-mouth disease antigen proteins have strong stability under the combined action of low concentrations of PEG and chloroform. Compared with the scheme of first using PEG to precipitate 146S, then reconstitute, and finally using high concentrations of chloroform to remove impurities (Comparative Group 4), the scheme of using PEI for impurity removal combined with the synergistic treatment of PEG and chloroform not only improved the antigen recovery rate but also significantly reduced the amount of chloroform used.

[0063] Example 4: Optimal PEG dosage for different antigen solutions

[0064] Reagents: PEG6000 (Merck), prepared as a 42% (m / V) PEG solution with water for injection, sterilized at 121°C for 20 minutes. Chloroform (Sinopharm), PEI (Aladdin), magnesium chloride (Sinopharm), sodium chloride (Sinopharm), Hepes (Millipore).

[0065] Antigen solution A: Foot-and-mouth disease virus at low density (3.62 × 10⁻⁶) in BHK-21 cells. 6 The cells were cultured in suspension (cell / ml) and then inactivated.

[0066] Antigen solution B: Foot-and-mouth disease virus transduced into BHK-21 cells at a high density (6.47 × 10⁻⁶). 6 The cells were cultured in suspension (cell / ml) and then inactivated.

[0067] PEI treatment: For antigen A and B treatment groups, PEI with a molecular weight of 10,000 and a final concentration of 0.005% (m / V) was added. After mixing thoroughly, the mixture was centrifuged at 7000 rpm using a disc centrifuge. The lower precipitate was discarded, and the supernatant was retained. For the comparison group of antigen A and B, the mixture was centrifuged at 7000 rpm using a disc centrifuge. The lower precipitate was discarded, and the supernatant was retained.

[0068] Ultrafiltration concentration: All four antigen solutions were concentrated to 1 / 10 of their original volume using a 500KD hollow fiber column.

[0069] Synergistic treatment of contaminating proteins with PEG and chloroform: For both antigen A and B treatment groups, 1% (m / V) PEG was added, mixed thoroughly, and then 2% (V / V) chloroform was added, mixed again, centrifuged at 60,000 rpm, the lower precipitate was discarded, and the supernatant was retained. The control groups of antigen A and B were not treated.

[0070] Salt concentration adjustment: 200 mM magnesium chloride was added to both antigen A and B treatment groups. No treatment was performed on the antigen A and B control groups.

[0071] The treatment of antigen solutions in each group is shown in Table 4.

[0072] Table 4

[0073]

[0074] Screening for the optimal PEG dosage for each antigen group: For each treatment group, take 5 samples, 40 ml each, and add PEG at final concentrations (m / V) of 4%, 5%, 6%, 7%, and 8%, respectively. Mix well and let stand for 4 hours. Centrifuge at 6000 rpm to collect the precipitate. Reconstitute the precipitate with 5 mM Hepes buffer (containing 400 mM sodium chloride, 1 mM magnesium chloride, and sodium hydroxide adjusted to pH 7.92) to a final volume of 10 ml.

[0075] Total 146S antigen content determination: 1 ml of sample was taken from each sample and the sucrose density gradient method was used for detection. The sample was directly loaded for detection according to the foot-and-mouth disease vaccine testing procedure in Announcement No. 2617 of the Ministry of Agriculture.

[0076] The 146S test results for each group of samples are shown in Table 5.

[0077] Table 5

[0078]

[0079] Combining the information from the four groups of antigen solutions in Table 4 and the results of different PEG treatments in Table 5, it can be seen that although the initial states of the antigen solutions in Treatment 1 and Treatment 2 were different, after removing nucleic acids and acidic proteins with PEI, removing impurities with low-concentration PEG combined with chloroform, and adjusting with salt, the optimal PEG dosage for both groups was 7% (m / V). However, the optimal PEG dosage for the two untreated control groups differed due to the difference in the state of the antigen solutions, being 6% (m / V) and 5% (m / V) respectively. Furthermore, even though Treatment 1 and Control 1 used the same antigen solution, and Treatment 2 and Control 2 used the same antigen solution, their optimal PEG dosages also differed after different treatments.

[0080] By using processes such as PEI to remove nucleic acids and acidic proteins, low-concentration PEG combined with chloroform for impurity removal, and salt adjustment, different antigen solutions can be made to achieve a relatively homogeneous state, which is conducive to the purification of target antigen proteins by PEG precipitation. This effectively avoids the incompatibility of purification parameters caused by upstream process optimization and changes, as well as batch-to-batch differences during production, ensuring the universal applicability of the purification process and the stability of antigen yield.

[0081] Example 5: Identification of Purification Effect

[0082] Reagents: PEG6000 (Merck), prepared as a 42% (m / V) PEG solution with water for injection, sterilized at 121°C for 20 minutes. Chloroform (Sinopharm Group).

[0083] Antigen solution: Foot-and-mouth disease virus was cultured in suspension in BHK-21 cells and then inactivated.

[0084] PEI treatment: Add PEI with a molecular weight of 70,000 and a final concentration of 0.005% (m / V) to the antigen solution, stir and mix well, then centrifuge at 6000 rpm using a disc centrifuge, discard the lower precipitate and retain the supernatant.

[0085] Ultrafiltration concentration: 500KD hollow fiber column, concentrated to 1 / 20 of the original volume.

[0086] Synergistic treatment of contaminating proteins with PEG and chloroform: Add PEG to a final concentration of 0.2% (m / V), mix well, then add chloroform to a final concentration of 5% (V / V), mix again, centrifuge at 60,000 rpm, discard the lower precipitate, and retain the supernatant.

[0087] Salt concentration adjustment: 100 mM magnesium chloride was added to both antigen A solution and antigen B solution treatment groups.

[0088] PEG purification: Add PEG to a final concentration of 7% (m / V), mix well, and let stand for 4 hours. Centrifuge at 8000 rpm to collect the precipitate. Reconstitute the precipitate with 20 mM Hepes buffer (containing 600 mM sodium chloride, 5 mM magnesium chloride, and sodium hydroxide adjusted to pH 7.88) to 1 / 4 of the concentrated antigen volume.

[0089] Purification effect HPLC analysis: An Agilent 1260 high performance liquid chromatograph equipped with a DAD detector was used. A size exclusion column was used for HPLC analysis of the purified antigen under the following conditions: flow rate 0.6 ml / min, detection wavelength 259 nm, and acquisition time 30 minutes. The chromatogram is shown below. Figure 1 As shown. By comparing the retention times of the pure 146S antigen under the same conditions, the peak with a retention time of 15.53 minutes was identified as the 146S antigen peak. According to the principle of size exclusion chromatography, large molecules have shorter flow paths and are eluted first, while small molecules have longer flow paths and are eluted later. Figure 1 As can be seen, large molecular weight proteins and / or nucleic acids have been removed, and the main component of the antigen solution is 146S antigen protein. Only between 18 and 20 minutes, a small amount of small molecular weight impurities remain. In summary, after PEI purification, ultrafiltration concentration, PEG and chloroform synergistic treatment of impurities, salt concentration adjustment, and PEG purification, the foot-and-mouth disease antigen achieved a high purity, fully meeting the requirements for foot-and-mouth disease vaccine preparation.

[0090] The specific embodiments of the present invention have been described above. It should be understood that the present invention is not limited to the specific embodiments described above, and those skilled in the art can make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.

Claims

1. A method for purifying foot-and-mouth disease inactivated antigen protein, characterized in that, The method includes the following steps: A1. Add PEI to the antigen solution, centrifuge to remove the precipitate, and retain the supernatant; The antigen solution was obtained by culturing foot-and-mouth disease virus in BHK-21 cells and then inactivating it. The pH of the PEI is 7.8-8.0, and the concentration of PEI in the antigen solution is 0.002-0.01% m / V; A2. The supernatant obtained in step A1 is concentrated by ultrafiltration using a hollow fiber column; A3. Add PEG to the concentrated antigen solution from step A2, stir and mix well, then add chloroform, stir and mix again, centrifuge to remove the precipitate, and retain the supernatant. The concentration of PEG in the antigen solution is 0.2-1.0% m / V; the concentration of chloroform in the antigen solution is 2-5% V / V. A4. Add an appropriate amount of salt to the supernatant obtained in step A3; A5. Add PEG to the supernatant obtained in step A4, centrifuge to collect the precipitate, dissolve the precipitate with a reconstitution solution, and filter to remove bacteria.

2. The purification method according to claim 1, characterized in that, In step A1, the molecular weight of the PEI is 1800-130000.

3. The purification method according to claim 1, characterized in that, In step A2, the pore size of the hollow fiber is 300-500KD, and it is concentrated to 1 / 10-1 / 20 of its original volume.

4. The purification method according to claim 1, characterized in that, In step A3, the molecular weight of the PEG is 4000-8000.

5. The purification method according to claim 1, characterized in that, In step A1 or step A3, the method for centrifuging to remove the precipitate is as follows: a disc centrifuge is used with a rotation speed of 5000-7000 rpm.

6. The purification method according to claim 1, characterized in that, In step A4, the salt includes at least one of 100-200 mM magnesium chloride or sodium sulfate and 500-1000 mM sodium chloride.

7. The purification method according to claim 1, characterized in that, In step A5, the molecular weight of the PEG is 4000-8000, and the concentration of PEG in the supernatant is 5-7% m / V.

8. The purification method according to claim 1, characterized in that, In step A5, the method for removing precipitate by centrifugation is as follows: a disc centrifuge is used at a speed of 6000-8000 rpm.

9. The purification method according to claim 1, characterized in that, In step A5, the reconstitution solution is 5-20 mM Hepes, which includes 400-600 mM sodium chloride, 1-5 mM magnesium chloride, and has a pH of 7.6-8.0.

Citation Information

Patent Citations

  • Process for purifying antigen of foot and mouth disease vaccine

    CN101664549B

  • Method for foot-and-mouth disease vaccine concentration and purification

    CN102631673A

  • Aftosa totivirus particle vaccine composition as well as preparation method and application thereof

    CN104548085A